Positive surgical margins in patients undergoing robotic partial nephrectomy for renal tumors are associated with adverse oncologic outcomes, a study revealed.
An interim analysis suggests that axitinib given to patients with complex clear cell renal cell carcinoma tumors significantly reduces tumor size and complexity.
Immune checkpoint inhibitors may be more beneficial than tyrosine kinase inhibitors for patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma.
Study provides preliminary data on triple therapy for advanced RCC while clinicians await definitive answers from the ongoing phase 3 COSMIC-313 trial.
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
In a study of patients with RCC and venous thrombus who underwent radical nephrectomy and venous thrombectomy, the median overall survival was 56 months.